Experimental CAR-T therapy takes on Hard-to-Treat cancers
Disease control
Ongoing
This early-stage trial tests a new treatment for people with advanced solid tumors that have a specific marker called CLDN6. The treatment uses specially engineered immune cells (CAR-T cells) that target CLDN6, sometimes combined with a genetic booster (RNA-LPX) to enhance their …
Phase: PHASE1 • Sponsor: BioNTech Cell & Gene Therapies GmbH • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC